These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


162 related items for PubMed ID: 25691283

  • 1. Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of KRAS, BRAF, and PIK3CA Mutations and LINE-1 Methylation.
    Baba Y, Ishimoto T, Harada K, Kosumi K, Murata A, Miyake K, Hiyoshi Y, Kurashige J, Iwatsuki M, Iwagami S, Miyamoto Y, Sakamoto Y, Yoshida N, Oki E, Iyama K, Watanabe M, Baba H.
    Ann Surg Oncol; 2015 Oct; 22(11):3659-65. PubMed ID: 25691283
    [Abstract] [Full Text] [Related]

  • 2. Chromosomal instability associated with global DNA hypomethylation is associated with the initiation and progression of esophageal squamous cell carcinoma.
    Kawano H, Saeki H, Kitao H, Tsuda Y, Otsu H, Ando K, Ito S, Egashira A, Oki E, Morita M, Oda Y, Maehara Y.
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S696-702. PubMed ID: 24898425
    [Abstract] [Full Text] [Related]

  • 3. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
    Kwon MJ, Kim JW, Jung JP, Cho JW, Nam ES, Cho SJ, Kim JS, Park HR, Min SK, Seo J, Min KW, Kim DH, Jeon JY.
    Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
    [Abstract] [Full Text] [Related]

  • 4. Basaloid squamous cell carcinoma of the esophagus: assessment for high-risk human papillomavirus and related molecular markers.
    Bellizzi AM, Woodford RL, Moskaluk CA, Jones DR, Kozower BD, Stelow EB.
    Am J Surg Pathol; 2009 Nov; 33(11):1608-14. PubMed ID: 19738459
    [Abstract] [Full Text] [Related]

  • 5. Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis.
    Sarbia M, Verreet P, Bittinger F, Dutkowski P, Heep H, Willers R, Gabbert HE.
    Cancer; 1997 May 15; 79(10):1871-8. PubMed ID: 9149011
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma.
    Kosumi K, Baba Y, Ishimoto T, Harada K, Nakamura K, Ohuchi M, Kiyozumi Y, Izumi D, Tokunaga R, Taki K, Higashi T, Miyata T, Shigaki H, Kurashige J, Hiyoshi Y, Iwatsuki M, Iwagami S, Sakamoto Y, Miyamoto Y, Yoshida N, Oki E, Watanabe M, Baba H.
    Med Oncol; 2016 Mar 15; 33(3):26. PubMed ID: 26880326
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Integrated molecular characterization of esophageal basaloid squamous cell carcinoma: a subtype with distinct RNA expression pattern and immune characteristics, but no specific genetic mutations.
    Li Y, Liu L, Pan Y, Fang F, Xie T, Cheng N, Guo C, Xue X, Zeng H, Xue L.
    J Pathol; 2023 Feb 15; 259(2):136-148. PubMed ID: 36371676
    [Abstract] [Full Text] [Related]

  • 10. Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors.
    Bidinotto LT, Véo CA, Loaiza EA, De França AP, Lorenzi AT, Rosa LA, De Oliveira CM, Levi JE, Scapulatempo-Neto C, Longatto-Filho A, Reis RM.
    Mol Med Rep; 2016 Oct 15; 14(4):3791-7. PubMed ID: 27573925
    [Abstract] [Full Text] [Related]

  • 11. KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.
    Zhou L, Baba Y, Kitano Y, Miyake K, Zhang X, Yamamura K, Kosumi K, Kaida T, Arima K, Taki K, Higashi T, Imai K, Hashimoto D, Yamashita Y, Chikamoto A, Beppu T, Tan X, Baba H.
    Med Oncol; 2016 Apr 15; 33(4):32. PubMed ID: 26927447
    [Abstract] [Full Text] [Related]

  • 12. Identification of molecular targets in vulvar cancers.
    Palisoul ML, Mullen MM, Feldman R, Thaker PH.
    Gynecol Oncol; 2017 Aug 15; 146(2):305-313. PubMed ID: 28536037
    [Abstract] [Full Text] [Related]

  • 13. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
    Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE.
    Clin Cancer Res; 2010 Feb 01; 16(3):790-9. PubMed ID: 20103678
    [Abstract] [Full Text] [Related]

  • 14. KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).
    Casadei Gardini A, Capelli L, Ulivi P, Giannini M, Freier E, Tamberi S, Scarpi E, Passardi A, Zoli W, Ragazzini A, Amadori D, Frassineti GL.
    PLoS One; 2014 Feb 01; 9(3):e92071. PubMed ID: 24642661
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative analysis of basaloid and typical squamous cell carcinoma of the oesophagus: a molecular biological and immunohistochemical study.
    Owonikoko T, Loberg C, Gabbert HE, Sarbia M.
    J Pathol; 2001 Feb 01; 193(2):155-61. PubMed ID: 11180160
    [Abstract] [Full Text] [Related]

  • 17. Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival.
    Mima K, Nowak JA, Qian ZR, Cao Y, Song M, Masugi Y, Shi Y, da Silva A, Gu M, Li W, Hamada T, Zhang X, Wu K, Meyerhardt JA, Baba H, Giovannucci EL, Chan AT, Fuchs CS, Ogino S, Nishihara R.
    Oncotarget; 2016 Aug 23; 7(34):55098-55109. PubMed ID: 27391152
    [Abstract] [Full Text] [Related]

  • 18. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
    Lee HK, Kwon MJ, Ra YJ, Lee HS, Kim HS, Nam ES, Cho SJ, Park HR, Min SK, Seo J, Choe JY, Min KW, Kang SY.
    Diagn Pathol; 2020 Oct 14; 15(1):126. PubMed ID: 33054840
    [Abstract] [Full Text] [Related]

  • 19. Expression of Bcl-2 and amplification of c-myc are frequent in basaloid squamous cell carcinomas of the esophagus.
    Sarbia M, Loberg C, Wolter M, Arjumand J, Heep H, Reifenberger G, Gabbert HE.
    Am J Pathol; 1999 Oct 14; 155(4):1027-32. PubMed ID: 10514383
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.